Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
EBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

MoonLake Immunotherapeutics (MLTX) Shares Outstanding (2020 - 2026)

MoonLake Immunotherapeutics' Shares Outstanding history spans 7 years, with the latest figure at $72.1 million for Q1 2026.

  • Quarterly Shares Outstanding rose 13.64% to $72.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $72.1 million through Mar 2026, up 13.64% year-over-year, with the annual reading at $71.4 million for FY2025, 8384.04% up from the prior year.
  • Shares Outstanding came in at $72.1 million for Q1 2026, up from $71.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $72.1 million in Q1 2026 to a low of $841269.0 in Q3 2024.
  • The 5-year median for Shares Outstanding is $53.6 million (2023), against an average of $46.4 million.
  • Year-over-year, Shares Outstanding plummeted 98.43% in 2024 and then soared 8384.04% in 2025.
  • MoonLake Immunotherapeutics' Shares Outstanding stood at $39.0 million in 2022, then tumbled by 93.57% to $2.5 million in 2023, then plummeted by 66.42% to $841269.0 in 2024, then skyrocketed by 8384.04% to $71.4 million in 2025, then rose by 1.07% to $72.1 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Shares Outstanding are $72.1 million (Q1 2026), $71.4 million (Q4 2025), and $64.2 million (Q3 2025).